The Biomarker Development Center (BDC) is a public-private partnership supported by a number of companies. These partners collaborate closely with the BDC on novel technological developments in the area of liquid chromatography – mass spectrometry and ultra-high sensitivity immunoassays. The expertise of these partners together with the input of the stakeholders is critical to BDC's success, as it allows us to remain at the technological forefront.
Waters Corporation is a leading developer of LC-MS technologies and systems for health sciences research and diagnostics, providing researchers of complex diseases with analytical tools to help make breakthrough discoveries, as well those required to translate discoveries into improved diagnostics. These tools and technologies allow the BDC to tackle current issues related to the application of LC-MS/MS in the selected reaction monitoring mode (SRM) for the specific and sensitivity quantification of protein biomarkers in complex biological samples.
Bruker Daltonik GmbH is a leading developer of Matrix-Assisted Laser Desorption mass spectrometers and will collaborate with the BDC in the area of high-throughput mass spectrometry. Despite its exquisite selectivity, mass spectrometry is currently not a mainstream analytical approach in clinical chemistry and other fields, where throughput and cost are critical. The BDC and Bruker have the common goal to change this situation.
PepScan B.V. is a provider of standardized synthetic peptides that serve as reference compounds in mass spectrometry-based assays. As a small-medium enterprise (SME), PepScan collaborates with the BDC in the area of providing standards for quantitative mass spectrometry for both SRM-based and MALDI-based assays.
Singulex Inc. is a highly innovative developer of single-molecule detection-based immunoassays with unprecedented sensitivity. Combining Singulex' technology with the disease-oriented projects of the BDC provides a unique opportunity to investigate the sub-pM concentration range in complex biological samples for biomarkers that went so far undetected.
Cell Signaling Technologies Inc. is a leader in the area of anti-phosphosite antibodies to detect post-translationally-modified proteins. By collaborating with the BDC we will have access to these highly specific antibodies for immunoaffinity-mass spectrometry analyses as well as for high-sensitivity immunoassays.
Avacta Life Sciences has developed a new alternative to antibodies and aptamers called Affimers. Based on a small protein scaffold that can be engineered to bind with high specificity and affinity to a wide range of protein targets, Affimers are engineered affinity proteins that are set to revolutionize the reagents market. Affimers can be used for a wide range of applications in diagnostics, drug/biomarker discovery and biotech research & development.